Roche Pharma launches PHESGO in India for the treatment of HER-2 positive breast Cancer

It is also the world’s first subcutaneous therapy for breast cancer that offers faster, more comfortable administration of Perjeta and Herceptin under the skin in just minutes, compared to multiple hours with standard intravenous administration, the pharma company stated.

New Delhi : Roche Pharma on Thursday announced the launch of PHESGO, the fixed dose
combination of two monoclonal antibodies in oncology for the treatment of HER-2 positive
breast cancer now available in India. The drug combines two proven blockbuster monoclonal
antibodies: Perjeta® (pertuzumab) and Herceptin® (trastuzumab) in a single vial for
subcutaneous administration. The subcutaneous injection in combination with intravenous (IV)
chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.


Informing that this is the first time that Roche Pharma has combined two monoclonal antibodies
that can be administered by a single SC injection, the company also stated that it is also the
world’s first subcutaneous therapy for breast cancer that offers faster, more comfortable
administration of Perjeta and Herceptin under the skin in just minutes, compared to multiple
hours with standard intravenous administration.


“It is administered as a single injection just under the skin in the thigh. Takes a few minutes
compared to hours with IV formulations for each round of treatment, thus reducing chair time for
patients by 90 per cent. Provides a faster, more convenient, and less invasive means to receive
breast cancer therapy Faster administration through PHESGO gives the confidence and frees
up time for everyone (patients, caregivers, doctors and paramedical staff), shorter
appointments, freeing up time of HCPs to treat more patients,” the company said in a statement.